205 related articles for article (PubMed ID: 25837771)
1. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
2. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
3. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
[TBL] [Abstract][Full Text] [Related]
5. Applications of Biophysics in High-Throughput Screening Hit Validation.
Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
[TBL] [Abstract][Full Text] [Related]
6. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
7. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
8. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.
Linke P; Amaning K; Maschberger M; Vallee F; Steier V; Baaske P; Duhr S; Breitsprecher D; Rak A
J Biomol Screen; 2016 Apr; 21(4):414-21. PubMed ID: 26637553
[TBL] [Abstract][Full Text] [Related]
9. An Alternative Thiol-Reactive Dye to Analyze Ligand Interactions with the Chemokine Receptor CXCR2 Using a New Thermal Shift Assay Format.
Bergsdorf C; Fiez-Vandal C; Sykes DA; Bernet P; Aussenac S; Charlton SJ; Schopfer U; Ottl J; Duckely M
J Biomol Screen; 2016 Mar; 21(3):243-51. PubMed ID: 26644402
[TBL] [Abstract][Full Text] [Related]
10. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
[TBL] [Abstract][Full Text] [Related]
11. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
12. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
14. High-throughput differential scanning fluorimetry (DSF) and cellular thermal shift assays (CETSA): Shifting from manual to automated screening.
Hansel CS; Lanne A; Rowlands H; Shaw J; Collier MJ; Plant H
SLAS Technol; 2023 Dec; 28(6):411-415. PubMed ID: 37598756
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
[TBL] [Abstract][Full Text] [Related]
17. A three-stage biophysical screening cascade for fragment-based drug discovery.
Mashalidis EH; Śledź P; Lang S; Abell C
Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
[TBL] [Abstract][Full Text] [Related]
18. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry for fragment screening.
Chan DS; Whitehouse AJ; Coyne AG; Abell C
Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
[TBL] [Abstract][Full Text] [Related]
20. Hit-to-Lead: Hit Validation and Assessment.
Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
